The protection rate of GlaxoSmithKline's RTS,S, an experimental malaria vaccine for children, reaches as high as 53% initially, but decreases after eight months, protecting 16.8% of children over a four-year period, according to a study in the New England Journal of Medicine. Since the findings were based on a small, midstage trial, they failed to "provide definitive answers about the duration of protection or how the vaccine candidate works in different malaria transmission settings," a GSK spokeswoman said.

Full Story:

Related Summaries